Effect of memantin in treatment of patients with schizophrenia
Not Applicable
- Conditions
- schizophrenia.Schizophrenia, schizotypal and delusional disorderF20,F21,F2
- Registration Number
- IRCT2014092819320N1
- Lead Sponsor
- Vice chancellor for research of Isfahan Univercity of Medical science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
inclusion criteria:age group 18-65 ; no mental retardation ;no pregnancy or milking ;diagnosis of schizophrenia for at least 2 years;treatment with atypical anti psychotic from 3 month ago;do not have ECT during 2 week ago
Exclusion criteria:allergic to memantin;addiction or dependency to substance or drugs ;other psychiatric disorder or serious neurological deficit.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of life. Timepoint: at base line,each 4 weeks to 12weeks. Method of measurement: Quality Of Life scale of schizophrenia.;Global Function. Timepoint: at baseline,each 4 weeks to 12weeks. Method of measurement: Global Assesment Of Functioning.;Possitive and negative symptoms. Timepoint: at base line, each 4 weeks to12 weeks. Method of measurement: Possitive And Negative Symptom Scale.;Depression. Timepoint: at base line,each 4 weeks to12 weeks. Method of measurement: Calgary Depressive Scale for Schizophrenia.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: during 12 weeks of study. Method of measurement: history of patient and his/her companion and physical exam.